Table I.
Role of factors regulating m6A in human cancer.
| Cancer type | Cell types examined | Associated proteins and expression patterns | Target genes (effects on their expression) | (Refs.) |
|---|---|---|---|---|
| Breast cancer | MDA-MB-231, MDA-MB-435, MCF-7, ZR75.1, T47D, BT-474, HCC-1954, SUM-149, SUM-159 | ALKBH5: Upregulated | NANOG (activated) | (23,24) |
| AML | WTAP: Peripheral blood mononuclear cells from AML patients | WTAP: CNV | WTAP-related: Not identified METTL3-related: PTEN, | (25–30) |
| METTL3: MOLM13, THP-1, MV4-11, | METTL3: Upregulated | c-MYC and BCL2 (activated) | ||
| NOMO-1, HL-60, KG-1, HEL, | ALKBH5: Loss of CNV | ALKBH5-related: Not identified | ||
| OCI-AML2, OCI-AML3, EOL-1 and AML patient samples | FTO: Upregulated | FTO-related: ASB2 and RARA (repressed) | ||
| ALKBH5: Database in TCGA Research Network FTO: Bone marrow cells isolated from primary MLL-rearranged AML patients | ||||
| Glioblastoma | Hs683, SW1783, U87MG, LN229, U251MG, GBM05 and patient-derived glioblastoma cells | ALKBH5: Upregulated | ALKBH5-related: FOXM1 (activated) | (31) |
| Lung cancer | A549, H1299 and H1792 | METTL3: Upregulated | Not identified | (34) |
| Liver cancer | Patient-derived HCC cells | METTL3: Upregulated | SOCS2 (repressed) | (35) |
m6A, N6-methyladenosine; WTAP, Wilms's tumor protein 1 (WT1)-associated protein; CNV, copy number variations; AML, acute myeloid leukemia; METTL3, methyltransferase-like protein 3; ALKBH5, alkylation repair homolog 5; FTO, fat mass and obesity-associated protein; PTEN, phosphatase and tensin homolog; Myc, myelocytomatosis oncogene; Bcl-2, B-cell lymphoma 2; TCGA, The Cancer Genome Atlas; ASB2, ankyrin repeat and SOCS box containing 2; RARA, retinoic acid receptor alpha; FOXM1, forkhead box protein M1; SOCS2, suppressor of cytokine signaling 2; HCC, hepatocellular carcinoma.